283 related articles for article (PubMed ID: 17606482)
1. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH
J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria.
Grare M; Mourer M; Fontanay S; Regnouf-de-Vains JB; Finance C; Duval RE
J Antimicrob Chemother; 2007 Sep; 60(3):575-81. PubMed ID: 17626025
[TBL] [Abstract][Full Text] [Related]
3. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Bogdanovich T; Clark C; Kosowska-Shick K; Dewasse B; McGhee P; Appelbaum PC
Antimicrob Agents Chemother; 2007 Nov; 51(11):4191-5. PubMed ID: 17875997
[TBL] [Abstract][Full Text] [Related]
4. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Yun IN; Kim CM; Kim JM; Kwak JH
Int J Antimicrob Agents; 2007 Nov; 30(5):446-51. PubMed ID: 17723291
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of LCB01-0062, a novel oxazolidinone.
Jung SJ; Yun IN; Park HS; Lee HH; Jeong JW; Kim YZ; Cho YL; Kwak JH
Int J Antimicrob Agents; 2012 Dec; 40(6):539-43. PubMed ID: 23058227
[TBL] [Abstract][Full Text] [Related]
6. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
7. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
Escaich S; Prouvensier L; Saccomani M; Durant L; Oxoby M; Gerusz V; Moreau F; Vongsouthi V; Maher K; Morrissey I; Soulama-Mouze C
Antimicrob Agents Chemother; 2011 Oct; 55(10):4692-7. PubMed ID: 21825292
[TBL] [Abstract][Full Text] [Related]
8. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.
Flamm RK; Rhomberg PR; Kaplan N; Jones RN; Farrell DJ
Antimicrob Agents Chemother; 2015 May; 59(5):2583-7. PubMed ID: 25691627
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
11. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.
Yum JH; Kim CK; Yong D; Lee K; Chong Y; Kim CM; Kim JM; Ro S; Cho JM
Antimicrob Agents Chemother; 2007 Jul; 51(7):2591-3. PubMed ID: 17420210
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
[TBL] [Abstract][Full Text] [Related]
15. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
Sultan T; Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.
Oh SH; Kim J; Baek SY; Chae SE; Park HS; Cho YL; Kwak JH
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273820
[TBL] [Abstract][Full Text] [Related]
20. Cationic compounds with activity against multidrug-resistant bacteria: interest of a new compound compared with two older antiseptics, hexamidine and chlorhexidine.
Grare M; Dibama HM; Lafosse S; Ribon A; Mourer M; Regnouf-de-Vains JB; Finance C; Duval RE
Clin Microbiol Infect; 2010 May; 16(5):432-8. PubMed ID: 19456831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
